Vasoactive medications — vasopressors and inotropes — are among the most powerful and unforgiving drugs administered in critical care. A vasopressor raises mean arterial pressure (MAP) by constricting blood vessels or increasing cardiac output. An inotrope improves myocardial contractility to boost the failing heart. In practice, many agents do both, and understanding the difference at the receptor level is what separates a nurse who titrates safely from one who causes harm.
These drugs are used almost exclusively in ICU, step-down, and emergency department settings — for septic shock, cardiogenic shock, neurogenic shock, anaphylaxis, and cardiac arrest. They are administered as continuous infusions, titrated to hemodynamic targets, and require near-constant monitoring. Dosing errors, infusion failures, and line extravasation can be fatal within minutes. This guide covers every vasoactive agent a nurse will encounter — receptor pharmacology, dose ranges, hemodynamic effects, shock-type matching, safe administration, extravasation management, and the NCLEX traps that catch students most often.
For a foundational overview of the four shock types and their hemodynamic profiles, review that reference first — this guide builds directly on that framework.
Receptor pharmacology primer
Vasoactive drugs work by binding to adrenergic receptors on the heart and blood vessels, or to non-adrenergic receptors (vasopressin V1). Knowing which receptor a drug hits tells you exactly what it will do to heart rate, contractility, vascular resistance, and blood pressure.
Alpha-1 (α1) receptors are located on vascular smooth muscle throughout the body. When stimulated, α1 causes vasoconstriction, increasing systemic vascular resistance (SVR) and raising MAP. There is no direct effect on heart rate or contractility. Phenylephrine is a pure α1 agonist; norepinephrine and epinephrine have strong α1 activity.
Beta-1 (β1) receptors are located primarily in the heart. Beta-1 stimulation produces three effects: inotropy (increased contractility), chronotropy (increased heart rate), and dromotropy (faster conduction through the AV node). The result is increased cardiac output (CO). Dobutamine is the prototypical β1 agonist; norepinephrine has modest β1 activity.
Beta-2 (β2) receptors are located in bronchial smooth muscle and peripheral blood vessels. Beta-2 stimulation causes bronchodilation and peripheral vasodilation — the opposite vascular effect of α1. Epinephrine has significant β2 activity, which partly limits its vasopressor effect. Dobutamine has mild β2 activity, contributing to SVR reduction.
Dopaminergic (DA1) receptors are located in renal and mesenteric vasculature. Dopaminergic stimulation causes selective vasodilation in these beds — theoretically increasing renal perfusion. At low doses, dopamine acts primarily on DA1 receptors, though the clinical significance of this renal effect has been largely debunked in sepsis trials.
Vasopressin V1 receptors are located on vascular smooth muscle. Vasopressin (antidiuretic hormone, ADH) at pharmacological doses binds V1 to produce direct vasoconstriction independent of adrenergic pathways — useful when catecholamine receptors are downregulated in prolonged septic shock.
Understanding these receptors makes every drug below predictable rather than memorized.
Drug-by-drug profiles
Vasopressor and inotrope quick-reference
| Drug | Primary receptor | Dose range | MAP effect | HR effect | CO effect | Primary indication | Key nursing note |
|---|---|---|---|---|---|---|---|
| Norepinephrine (Levophed) | α1 dominant, β1 mild | 0.01–3 mcg/kg/min | ↑↑↑ | ↔ or ↑ | ↔ or ↑ | Septic shock (first-line) | Extravasation causes tissue necrosis — central line required |
| Epinephrine | α1, β1, β2 (all strong) | 0.01–1 mcg/kg/min | ↑↑↑ | ↑↑ | ↑↑ | Anaphylaxis, cardiac arrest, refractory shock | Tachyarrhythmia risk; lactic acidosis at high doses |
| Dopamine | DA1 (low), β1 (mid), α1 (high) | 1–20+ mcg/kg/min | ↑ (dose-dependent) | ↑ | ↑ | Largely replaced by NE in sepsis; still used in bradycardia | Dose-dependent receptor shifts; more arrhythmias than NE |
| Vasopressin | V1 (vascular) | 0.03–0.04 units/min (fixed) | ↑↑ | ↓ (reflex) | ↔ | Septic shock adjunct (add to NE) | NOT titrated; mesenteric ischemia risk |
| Phenylephrine (Neo-Synephrine) | α1 pure | 0.5–6 mcg/kg/min | ↑↑ | ↓ (reflex bradycardia) | ↓ | Neurogenic shock; tachycardia-related hypotension | No beta activity; reflex bradycardia expected |
| Dobutamine | β1 dominant, β2 mild | 2–20 mcg/kg/min | ↔ or ↓ | ↑ | ↑↑ | Cardiogenic shock, low-output states | No vasoconstriction — contraindicated in hypovolemia |
| Milrinone | PDE-3 inhibitor (non-adrenergic) | 0.25–0.75 mcg/kg/min | ↓ | ↔ or ↑ | ↑↑ | Cardiac failure with high SVR (inodilator) | Renally cleared — dose-reduce in AKI; sustained hypotension risk |
Norepinephrine (Levophed)
Mechanism: Norepinephrine is an endogenous catecholamine with dominant α1 activity and mild β1 activity. It powerfully constricts peripheral vasculature (raising SVR and MAP) while providing modest inotropy. The combined effect is a significant rise in MAP with relatively little change in heart rate.
Dose: 0.01–3 mcg/kg/min, titrated to MAP goal. Most patients in septic shock respond in the 0.1–0.5 mcg/kg/min range; requirements above 1 mcg/kg/min indicate severe or refractory shock.
Hemodynamic effects: MAP rises significantly. Heart rate is generally stable or mildly increased. Cardiac output may rise modestly (from β1 inotropy) or remain unchanged. SVR increases substantially.
Primary indication: First-line vasopressor in septic shock per the Surviving Sepsis Campaign guidelines. Also used in other distributive shock states (neurogenic, vasodilatory post-cardiac bypass).
Key nursing considerations:
- Extravasation is a medical emergency. Norepinephrine causes severe arterial vasoconstriction in tissue — extravasation leads to tissue necrosis and digital ischemia. A central line is mandatory. If peripheral administration is unavoidable in extremis, use a large proximal vein (antecubital), monitor every 30–60 minutes, and have phentolamine available.
- Monitor for digital ischemia at high doses: check fingertips and toes every 2–4 hours. Blanching or mottling of fingers indicates severe peripheral vasoconstriction.
- Dose changes should be documented in real time with the exact mcg/kg/min and the hemodynamic response.
- Double-check the concentration calculation with a second RN before starting the infusion.
Epinephrine
Mechanism: Epinephrine stimulates all three adrenergic receptors — α1 (vasoconstriction), β1 (inotropy + chronotropy), and β2 (bronchodilation, peripheral vasodilation). At low doses, β effects dominate; at high doses, α1 vasoconstriction predominates. The net effect across the full dose range is a rise in MAP and a significant increase in cardiac output, at the cost of markedly elevated heart rate.
Dose: 0.01–1 mcg/kg/min IV infusion for shock states. For anaphylaxis: 0.3–0.5 mg IM (1:1,000 solution) as first-line; IV epinephrine (1:10,000 solution) reserved for refractory anaphylaxis or cardiac arrest.
Hemodynamic effects: MAP rises dramatically. Heart rate increases substantially — tachycardia is near-universal. Cardiac output increases significantly. SVR increases.
Primary indication: Anaphylactic shock (IM epinephrine is the first-line treatment — not IV), cardiac arrest (1 mg IV every 3–5 min per ACLS), and refractory septic shock when norepinephrine alone is insufficient.
Key nursing considerations:
- Tachyarrhythmias are the primary risk. Sinus tachycardia is expected; atrial fibrillation, ventricular tachycardia, and ventricular fibrillation can occur. Continuous cardiac monitoring is non-negotiable. See the cardiac arrhythmias nursing guide for arrhythmia recognition and management.
- Lactic acidosis at high doses results from epinephrine-driven aerobic glycolysis and peripheral vasoconstriction impairing tissue perfusion. A rising lactate in a patient on high-dose epinephrine may reflect drug effect rather than worsening shock — clinical correlation is essential.
- In anaphylaxis, IM epinephrine into the lateral thigh is always first. Only escalate to IV if IM fails and the patient is in cardiac arrest or severe cardiovascular collapse.
- Extravasation risk is high — central line required for infusion.
Dopamine
Mechanism: Dopamine has dose-dependent receptor activity that shifts with increasing rate:
- Low dose (1–5 mcg/kg/min): Acts on dopaminergic (DA1) receptors → renal and mesenteric vasodilation. Once believed to protect renal function; clinical trials have not confirmed a meaningful benefit in sepsis-associated AKI.
- Mid dose (5–10 mcg/kg/min): β1 receptors dominate → increased inotropy and chronotropy, rising cardiac output.
- High dose (>10 mcg/kg/min): α1 receptors dominate → vasoconstriction and rising MAP, similar to norepinephrine but with more tachycardia.
Dose: 1–20+ mcg/kg/min, titrated by effect. The dose-receptor relationship is approximate — individual responses vary.
Hemodynamic effects: MAP rises (more pronounced at high doses). Heart rate increases at all doses — more so than with norepinephrine. Cardiac output increases, particularly at mid doses.
Primary indication: Dopamine has largely fallen out of favor for septic shock. The SOAP II trial (De Backer et al., NEJM 2010) compared dopamine to norepinephrine as first-line vasopressor in shock and found higher rates of arrhythmias with dopamine and higher 28-day mortality in cardiogenic shock patients. It remains an option when bradycardia with hypotension is present (mid-dose dopamine raises both HR and MAP). Some centers still use it in hemodynamically unstable bradycardia when atropine has failed.
Key nursing considerations:
- Dopamine causes significantly more arrhythmias than norepinephrine — atrial fibrillation is common.
- The dose-receptor shift is not a clean boundary. At mid-range doses, some α1 and some DA1 activity persists simultaneously.
- Extravasation causes tissue necrosis — central line required.
- “Renal-dose dopamine” (low-dose) for kidney protection is not supported by evidence. Do not assume low-dose dopamine is protective.
Vasopressin
Mechanism: Vasopressin (antidiuretic hormone) at pharmacological doses binds V1 receptors on vascular smooth muscle, causing direct vasoconstriction independent of adrenergic pathways. This makes it uniquely useful in prolonged septic shock, where adrenergic receptor downregulation (tachyphylaxis) reduces the effectiveness of catecholamines. Vasopressin also has antidiuretic effects (V2 receptors in the kidney) and mild corticotropin-releasing effects.
Dose: Fixed at 0.03–0.04 units/min. Vasopressin is NOT titrated — this is a critical NCLEX and clinical distinction. It is added as a fixed-rate adjunct to norepinephrine.
Hemodynamic effects: MAP rises. Heart rate may decrease reflexively (baroreceptor response to increased SVR). Cardiac output is generally unchanged.
Primary indication: Septic shock adjunct when norepinephrine alone is insufficient to achieve MAP ≥65 mmHg. The VASST trial showed adding vasopressin (0.03 units/min) to norepinephrine allowed norepinephrine dose reduction in less severe septic shock (norepinephrine ≤15 mcg/min stratum), though overall 28-day mortality was similar between groups.
Key nursing considerations:
- Never titrate vasopressin. The dose is fixed. Only norepinephrine is titrated alongside it.
- Mesenteric ischemia is the most serious complication. Splanchnic vasoconstriction from vasopressin can reduce gut perfusion. Monitor for abdominal pain, distension, rising lactate, and blood in stool.
- Skin necrosis and digital ischemia can occur with high-dose or prolonged vasopressin.
- Central line required.
- Vasopressin infusions should be labeled distinctly — the fixed-dose concept is counterintuitive to staff accustomed to titrating catecholamines.
Phenylephrine (Neo-Synephrine)
Mechanism: Phenylephrine is a pure α1 agonist with no beta activity whatsoever. It constricts peripheral vasculature, raises SVR and MAP, and produces reflex bradycardia via baroreceptor activation. Because it has no β1 activity, it does not increase heart rate or contractility.
Dose: 0.5–6 mcg/kg/min, titrated to MAP goal.
Hemodynamic effects: MAP rises substantially. Heart rate decreases (reflex bradycardia). Cardiac output typically decreases (higher afterload with no compensatory inotropy, lower heart rate). SVR increases significantly.
Primary indication: Two main scenarios:
- Neurogenic shock — bradycardia plus hypotension from loss of sympathetic tone (spinal cord injury at T6 and above). Phenylephrine raises MAP without worsening bradycardia (unlike dopamine or epinephrine).
- Tachycardia-related hypotension — when a patient has dangerous tachycardia and hypotension simultaneously, a pure α1 agent avoids the chronotropic effect of catecholamines.
Also used intraoperatively for spinal anesthesia-induced hypotension (often as bolus doses).
Key nursing considerations:
- Expect reflex bradycardia — this is a pharmacological effect, not a complication. However, severe bradycardia (HR <40) is a reason to reassess.
- Because cardiac output decreases, phenylephrine should be avoided in cardiogenic shock and hypovolemic shock — raising afterload without improving contractility worsens cardiac performance.
- No extravasation necrosis risk, but central line is still strongly preferred for continuous infusion.
- If the patient develops new-onset bradycardia on phenylephrine, reduce the dose before attributing it to another cause.
Dobutamine
Mechanism: Dobutamine is primarily a β1 agonist with mild β2 activity. It increases myocardial contractility (inotropy) and heart rate (chronotropy), raising cardiac output substantially. The β2 component causes mild peripheral vasodilation, which reduces SVR. The combined result is increased CO with decreased or unchanged MAP — the opposite of a vasopressor.
Dose: 2–20 mcg/kg/min, titrated to hemodynamic response.
Hemodynamic effects: Cardiac output rises significantly. Heart rate increases. MAP may decrease slightly (from β2-mediated SVR reduction) or remain unchanged. SVR decreases.
Primary indication: Cardiogenic shock and low-output heart failure where the primary problem is inadequate contractility rather than inadequate vascular tone. Often combined with a vasopressor (norepinephrine or vasopressin) when both low CO and hypotension are present.
Key nursing considerations:
- Contraindicated in hypovolemia. Without adequate preload, dobutamine’s vasodilation and tachycardia will worsen hypotension and produce no benefit in CO. Ensure adequate volume resuscitation before starting dobutamine. Review IV fluids nursing for resuscitation principles.
- Dobutamine causes tachycardia and can precipitate or worsen atrial fibrillation — continuous ECG monitoring required.
- Because dobutamine reduces MAP in some patients, it may need to be paired with a vasopressor.
- Does not require a central line by strict policy, but central line is strongly preferred for continuous vasoactive infusion.
- Tachyphylaxis (tolerance) can develop after 72–96 hours of continuous infusion.
Milrinone
Mechanism: Milrinone is a phosphodiesterase-3 (PDE-3) inhibitor, not an adrenergic agonist. It works by preventing the breakdown of cyclic AMP (cAMP) inside cardiac and vascular smooth muscle cells. In the heart, elevated cAMP increases contractility (inotropy). In blood vessels, elevated cAMP causes relaxation (vasodilation). The result is increased CO and decreased SVR simultaneously — milrinone is called an “inodilator” for this reason.
Dose: 0.25–0.75 mcg/kg/min continuous infusion. A loading dose (50 mcg/kg over 10 min) is sometimes used but frequently omitted in hemodynamically unstable patients due to the risk of precipitous hypotension.
Hemodynamic effects: Cardiac output rises. SVR falls. MAP decreases, sometimes substantially. Heart rate may increase mildly.
Primary indication: Cardiogenic shock or acute decompensated heart failure with elevated SVR (high afterload, low CO). Particularly useful when beta-receptors are downregulated from chronic beta-blocker use or prolonged heart failure — milrinone works downstream of the receptor, so receptor downregulation does not blunt its effect.
Key nursing considerations:
- Renally cleared — reduce dose in AKI. Accumulation causes prolonged hypotension and arrhythmias. Monitor creatinine and adjust dose with nephrology or pharmacy input.
- Sustained hypotension is the primary risk. Monitor MAP every 15 minutes after initiation or dose change. Have a vasopressor (norepinephrine) available and ready to add.
- Milrinone is NOT appropriate as a standalone agent when MAP is already low. It must be used alongside a vasopressor if MAP is inadequate.
- The loading dose is often skipped in unstable patients — confirm the attending’s intent before administering.
- Half-life is 2–3 hours in patients with normal renal function; much longer in AKI. Hypotension from milrinone can persist long after the infusion is reduced.
Shock-type matching
Selecting the right vasoactive agent requires matching the drug’s mechanism to the underlying hemodynamic deficit. The wrong choice — dobutamine in a hypovolemic patient, phenylephrine in cardiogenic shock — can be fatal.
| Shock type | First-line agent | Second-line / adjunct | Key rationale |
|---|---|---|---|
| Septic shock | Norepinephrine | Vasopressin (add at 0.03 units/min); epinephrine if CO low | Distributive — SVR is low; NE raises SVR and MAP. SOAP II confirmed NE superiority over dopamine. Vasopressin spares catecholamine dose. Dobutamine added if ScvO2 <70% despite MAP ≥65. |
| Cardiogenic shock | Dobutamine or milrinone | Norepinephrine or vasopressin if also hypotensive; IABP | Problem is low CO (pump failure), not low SVR. Inotropes boost CO. Add vasopressor if MAP still inadequate. Phenylephrine is harmful — raises afterload with no inotropy. See IABP nursing guide. |
| Neurogenic shock | Phenylephrine or norepinephrine | Atropine for bradycardia; fluid resuscitation first | Loss of sympathetic tone — bradycardia AND hypotension. Pure α1 (phenylephrine) raises MAP without worsening bradycardia. NE (α1 + β1) is also reasonable — mild chronotropy may help. |
| Anaphylactic shock | Epinephrine IM (0.3–0.5 mg, 1:1,000) | IV epinephrine infusion for refractory cases; norepinephrine as backup | IM epinephrine is first-line always. IV is reserved for cardiac arrest or complete non-response to IM. Epinephrine reverses all pathophysiology simultaneously: bronchodilation (β2), inotropy (β1), vasoconstriction (α1), mast cell stabilization. |
| Hypovolemic shock | Fluid resuscitation — not vasopressors | Norepinephrine as temporizing bridge if MAP critically low | Vasopressors do not treat volume depletion. They buy time only. Correct the volume deficit. See IV fluids nursing. |
For the full hemodynamic framework of each shock type — SVR, CO, PCWP, clinical signs — see the shock nursing reference and the sepsis nursing guide for septic shock staging and bundles.
Nursing administration and titration
Central line requirement
All vasoactive infusions must run through a central venous catheter whenever possible. Vasopressors — particularly norepinephrine and dopamine — cause catastrophic tissue necrosis if they extravasate into soft tissue. Central access also allows CVP monitoring and ScvO2 sampling, which guide resuscitation targets.
If a central line is not yet placed and the patient’s MAP is critically low, peripheral vasopressor administration may be used as a short-term bridge (≤4 hours maximum). In this situation: use the largest, most proximal vein available (antecubital preferred), check the site for extravasation every 30–60 minutes, and have phentolamine drawn up and ready. Establish central access as soon as possible.
For complete central line insertion and maintenance nursing, see the central line nursing guide.
Concentration verification
Before hanging any vasoactive infusion:
- Confirm the drug, concentration, diluent, and bag volume match the pharmacy label and the physician order.
- Have a second RN independently verify the concentration and the pump programming — this is a two-nurse double-check, not a co-sign.
- Confirm the correct patient and the correct lumen (dedicate a lumen to each vasoactive drug when possible — never Y-site a vasoactive with a bolus medication without consulting pharmacy).
Dose calculation
Most vasoactive drugs are dosed in mcg/kg/min. The pump rate (mL/hr) is calculated as:
Rate (mL/hr) = [Dose (mcg/kg/min) × Weight (kg) × 60 min/hr] ÷ Concentration (mcg/mL)
Example: Norepinephrine 0.1 mcg/kg/min for a 70 kg patient, concentration 4 mg/250 mL (16 mcg/mL):
- Rate = (0.1 × 70 × 60) ÷ 16 = 420 ÷ 16 = 26.25 mL/hr
Most institutions use pharmacy-prepared standard concentrations — confirm the concentration on every bag.
Titration
Titrate vasopressors to a MAP target of ≥65 mmHg as the primary endpoint in septic shock (Surviving Sepsis Campaign guidelines, 2021). Higher targets (MAP ≥80 mmHg) have not been shown to improve outcomes in unselected patients but may be appropriate in patients with chronic hypertension or evidence of end-organ hypoperfusion at a MAP of 65.
Standard titration practice:
- Increase or decrease by 0.01–0.05 mcg/kg/min every 5–15 minutes, assessing MAP response after each change.
- Allow 5 minutes at minimum for hemodynamic equilibration before the next adjustment.
- Document every dose change in the medication administration record with the MAP at the time of change.
- If MAP is not responding to escalating doses, reassess volume status, confirm adequate vasopressor concentration, and consider adding a second agent.
Vasopressin (0.03–0.04 units/min) is not titrated — it is added at a fixed dose and removed as norepinephrine is weaned.
Continuous arterial line monitoring for MAP is strongly preferred during vasoactive infusions — see the arterial line nursing guide for insertion, zeroing, troubleshooting, and waveform interpretation.
Extravasation management
Norepinephrine, dopamine, epinephrine, and phenylephrine all cause local vasoconstriction and tissue ischemia on extravasation. Norepinephrine and dopamine carry the highest extravasation risk because they are most commonly given peripherally in emergencies and at highest concentrations.
| Drug | Extravasation risk | Tissue damage mechanism | Treatment |
|---|---|---|---|
| Norepinephrine (Levophed) | Very high | Intense α1 vasoconstriction → ischemic necrosis | Phentolamine 5–10 mg in 10 mL NS, injected SC into affected area within 12 hours; warm compresses; photograph and document; plastic surgery consult for significant necrosis |
| Dopamine | Very high | α1 vasoconstriction at high doses + direct cellular toxicity | Phentolamine 5–10 mg in 10 mL NS SC into affected area; same protocol as norepinephrine |
| Epinephrine | High | α1 vasoconstriction → local ischemia | Phentolamine SC injection; warm compresses; monitor for necrosis |
| Phenylephrine | Moderate | Pure α1 vasoconstriction | Phentolamine SC injection; warm compresses |
| Vasopressin | Moderate | V1-mediated vasoconstriction | Phentolamine SC injection; warm compresses; monitor for skin necrosis |
| Dobutamine | Low | β2 vasodilation — less ischemia risk | Standard extravasation protocol; hyaluronidase if significant swelling |
| Milrinone | Low | Vasodilatory — minimal ischemia risk | Standard extravasation protocol |
Phentolamine administration protocol
Phentolamine is an alpha-adrenergic blocker that directly counteracts the vasoconstriction causing tissue ischemia. Administer within 12 hours of extravasation for maximum efficacy — the window narrows rapidly.
Preparation: Dilute 5–10 mg phentolamine in 10 mL normal saline.
Injection technique: Using a small-gauge needle (25–27g), inject multiple small amounts (0.5–1 mL per injection) subcutaneously into the affected area, distributing the dose around the extravasation site. Do not inject directly into an already-necrotic area.
Documentation: Photograph the site before and after treatment. Mark the borders of the extravasation area with a skin pen. Document size, color, tissue turgor, and capillary refill. Notify the attending physician and wound care nurse.
Follow-up: Monitor the site every 30–60 minutes for the first 4 hours. Arrange plastic surgery consultation for any extravasation with visible skin blanching, blistering, or necrosis.
Hemodynamic monitoring alongside vasoactive drugs
Vasoactive medications demand continuous hemodynamic monitoring. Blind titration without real-time data invites overshoot and undershoot.
Arterial line (A-line): Provides beat-to-beat MAP monitoring, which is far more accurate and timely than non-invasive cuff pressure. Any patient on a continuous vasoactive infusion should have an arterial line placed as soon as feasible. See the arterial line nursing guide for zeroing, transducer positioning, and waveform interpretation.
CVP monitoring: Central venous pressure provides a rough estimate of preload and volume status, useful for guiding fluid resuscitation alongside vasopressors.
ScvO2: Central venous oxygen saturation (ScvO2) ≥70% indicates adequate oxygen delivery to tissues. ScvO2 <70% on norepinephrine suggests that MAP is restored but CO or oxygen delivery remains insufficient — a trigger to add dobutamine or reassess volume.
Drug-specific monitoring priorities
| Complication to monitor | Associated drug(s) | Nursing action |
|---|---|---|
| Tachyarrhythmias (AF, SVT, VT) | Epinephrine, dopamine, dobutamine | Continuous ECG; notify MD; consider dose reduction |
| Reflex bradycardia | Phenylephrine | Expected effect; treat only if HR <40 or hemodynamically significant |
| New atrial fibrillation | Dobutamine (most common), epinephrine | 12-lead ECG; rate vs rhythm control per MD order |
| Digital ischemia (fingertip mottling) | Norepinephrine (high dose), vasopressin | Check extremities every 2–4h; document; notify MD |
| Mesenteric ischemia | Vasopressin | Monitor abdomen, lactate, stool output; notify MD if concerned |
| Lactic acidosis | Epinephrine (high dose) | Trend lactate; correlate with clinical status; may be drug effect |
| Sustained hypotension | Milrinone, dobutamine | Add vasopressor; reduce infusion rate; assess volume status |
Weaning protocols
Weaning vasoactive medications is as carefully managed as initiation. Premature weaning causes hemodynamic deterioration; delayed weaning prolongs ICU stay and drug complications.
Indications to begin weaning:
- MAP has been stable at or above goal (≥65 mmHg) for at least 2–4 consecutive hours
- Fluid resuscitation is complete and the patient is no longer in a state of active shock
- Lactate is trending down toward normal (<2 mmol/L)
- Evidence of end-organ recovery (urine output improving, mental status clearing)
General weaning approach:
- Decrease by the smallest increment the pump allows — typically 0.01–0.05 mcg/kg/min every 15–30 minutes
- Observe MAP response for at least 15 minutes between reductions
- If MAP drops below goal after a reduction, hold the wean and reassess volume status and clinical condition
Weaning sequence:
- If the patient is on multiple vasopressors, wean one at a time — typically wean epinephrine or dopamine before norepinephrine
- Vasopressin is generally discontinued after norepinephrine is reduced to low doses (≤0.1 mcg/kg/min)
- Norepinephrine is typically weaned last — it is the most physiologically reliable vasopressor in septic shock
- Dobutamine is weaned independently of vasopressors, guided by cardiac output and ScvO2
Fluid reassessment before weaning: Many patients require a small fluid challenge (250–500 mL crystalloid) before vasopressor weaning to ensure adequate preload. Assess fluid responsiveness (passive leg raise, pulse pressure variation if mechanically ventilated) before adding volume.
Document every down-titration step with the time, new dose, and MAP response.
Patient safety considerations
Never bolus a vasoactive infusion. Vasopressor lines must never be flushed or bolused. Even a small volume of concentrated vasopressor delivered rapidly can cause severe hypertension, arrhythmia, or cardiac arrest. Use dedicated lumens; if a line must be cleared, do so at the prescribed infusion rate only.
Label all vasoactive lines clearly. Every vasoactive infusion line should be labeled at the insertion point and at the pump — drug name, concentration, and dose per mL. Use high-alert medication labeling per institutional policy.
Dedicated lumen policy. Where possible, run each vasoactive drug through its own dedicated central line lumen. Do not co-infuse vasoactive drugs with parenteral nutrition, blood products, or medications that may be incompatible.
Monitor for tachyphylaxis. With prolonged catecholamine infusions, receptor downregulation can reduce drug effect — higher doses are required for the same MAP response. If dose requirements are escalating without improvement, consider adding a second agent with a different mechanism (e.g., vasopressin to norepinephrine), reassess for new bleeding or new infection source, and consult critical care.
Two-nurse verification. All vasoactive drug changes — initiation, concentration changes, bag changes, dose changes — require a two-nurse independent verification. This is a mandatory safety standard and should never be skipped under time pressure.
Bag change continuity. When hanging a new bag, ensure the infusion rate is never interrupted — run the new bag in parallel for a brief overlap rather than stopping the infusion to change bags. MAP can drop precipitously within 30–60 seconds of vasopressor interruption in a vasodependent patient.
NCLEX high-yield section
Vasopressors and inotropes are tested heavily on NCLEX because they require integration of pharmacology, pathophysiology, and clinical judgment. These are the scenarios that catch students most often.
| # | NCLEX scenario / question stem | High-yield answer and rationale |
|---|---|---|
| 1 | A patient in septic shock has a MAP of 58 mmHg. The physician orders a vasopressor. Which drug is first-line? | Norepinephrine (Levophed). Surviving Sepsis guidelines recommend NE as first-line vasopressor in septic shock. Dopamine is second-line due to higher arrhythmia risk (SOAP II trial). |
| 2 | A nurse is hanging a norepinephrine infusion and the only available access is a peripheral IV. What is the priority action? | Use the largest, most proximal vein; check the site every 30–60 minutes for extravasation; obtain central access as soon as possible. Peripheral vasopressor use is a last resort, not standard practice. |
| 3 | A patient on norepinephrine develops a pale, painful area around their peripheral IV site. What is the priority intervention? | Stop the infusion; notify the MD; prepare phentolamine 5–10 mg in 10 mL NS for subcutaneous injection into the affected area. Phentolamine reverses vasoconstriction and limits necrosis if given within 12 hours. |
| 4 | The nurse is titrating vasopressin for a patient in septic shock. The MAP rises to 72 mmHg. What is the correct next step? | Do not titrate vasopressin. Vasopressin runs at a fixed dose (0.03–0.04 units/min). Titrate the catecholamine (norepinephrine) alongside it. This is the most commonly missed NCLEX fact about vasopressin. |
| 5 | A patient with cardiogenic shock has a MAP of 62 mmHg. The physician orders dobutamine. What should the nurse assess first? | Volume status / preload. Dobutamine causes vasodilation (β2) and will worsen hypotension in a hypovolemic patient. Confirm the patient is adequately resuscitated before starting. If MAP is critically low, a vasopressor should be added alongside dobutamine. |
| 6 | The MAP target in septic shock per Surviving Sepsis guidelines is: | ≥65 mmHg. Higher targets (≥80 mmHg) have not been shown to improve overall outcomes and increase vasopressor requirements. |
| 7 | A patient develops anaphylaxis with bronchospasm and hypotension after IV contrast. What is the first drug to administer? | Epinephrine 0.3–0.5 mg IM into the lateral thigh (1:1,000 solution). IM epinephrine — not IV, not antihistamines, not corticosteroids — is always first-line in anaphylaxis. |
| 8 | A patient is on phenylephrine for neurogenic shock. The heart rate drops to 42 bpm. What is the nurse's interpretation? | Expected reflex bradycardia from pure α1-mediated SVR increase activating baroreceptors. Notify the MD and monitor closely, but this is a known pharmacological effect. Phenylephrine has no β activity to raise HR. |
| 9 | Which vasopressor is associated with the highest risk of arrhythmias, and why? | Dopamine — particularly at mid-dose (β1 dominant). Its arrhythmogenic profile led to inferior outcomes in the SOAP II trial compared to norepinephrine in shock. |
| 10 | A patient on milrinone develops worsening hypotension. The nurse notes the creatinine has risen from 1.0 to 3.2 mg/dL over 48 hours. What is the most likely cause? | Milrinone accumulation due to AKI. Milrinone is renally cleared. In acute kidney injury, the half-life extends and the drug accumulates, causing prolonged hypotension and arrhythmias. Dose reduction and nephrology consult are required. |
| 11 | The nurse receives an order to "flush the vasopressor line." What is the correct response? | Clarify the order — vasopressor lines should never be bolused or flushed rapidly. Even a small bolus of concentrated vasopressor causes severe hypertension and arrhythmia. Clarify with the MD and follow institutional policy. |
| 12 | A patient in septic shock requires increasing doses of norepinephrine (now at 0.6 mcg/kg/min). ScvO2 is 65%. The MAP is 70 mmHg. What adjunct is most appropriate? | Add dobutamine to improve cardiac output and oxygen delivery. ScvO2 <70% despite adequate MAP indicates insufficient CO — an inotrope addresses this while the vasopressor maintains MAP. |
| 13 | Which drug would be most appropriate in a patient with neurogenic shock (T4 spinal injury, HR 48, MAP 54)? | Norepinephrine or phenylephrine. Neurogenic shock involves bradycardia and hypotension from sympathetic loss. Phenylephrine raises MAP without worsening bradycardia; NE adds mild chronotropy. Dopamine (mid-dose) is also used but carries more arrhythmia risk. |
| 14 | A nurse is preparing to wean norepinephrine. The MAP has been 70 mmHg for the past 3 hours. What other parameter should be assessed before weaning? | Lactate trend and volume status. MAP stability alone is not sufficient. Confirm lactate is trending toward normal, that active fluid resuscitation is complete, and that the patient has adequate preload before reducing the vasopressor. |
| 15 | The physician orders milrinone for a patient with heart failure and a MAP of 58 mmHg. The nurse's priority concern is: | Milrinone lowers MAP further (inodilator — reduces SVR). The MAP is already below goal. This patient likely needs a vasopressor added simultaneously, or the dose should be started very low with close monitoring. |
| 16 | "Renal-dose" dopamine (1–3 mcg/kg/min) is ordered to protect kidney function. How should the nurse respond? | This is not evidence-based practice. Clinical trials have not confirmed that low-dose dopamine prevents AKI or improves renal outcomes. The nurse should clarify the indication with the physician and document the order as received. |
| 17 | A patient on vasopressin develops abdominal distension, rising lactate, and bloody stool. What complication should the nurse suspect? | Mesenteric ischemia from splanchnic vasoconstriction. This is the most serious vasopressin complication. Notify the physician immediately — vasopressin may need to be discontinued and urgent surgical evaluation requested. |
| 18 | In cardiogenic shock, phenylephrine is ordered. The nurse should question this order because: | Phenylephrine raises afterload (SVR) without improving contractility. In cardiogenic shock, the failing heart cannot compensate for increased resistance — cardiac output falls further. The appropriate agent is an inotrope (dobutamine or milrinone). |
| 19 | Two nurses are required before starting a vasopressor infusion. The day shift nurse says "just start it — I'll witness-sign later." The correct response is: | Decline and perform the two-nurse verification before starting. Two-nurse independent verification is a mandatory safety standard for high-alert medications. It cannot be retroactively completed. Time pressure does not override this requirement. |
| 20 | A patient on dobutamine develops new-onset atrial fibrillation with a ventricular rate of 140. The MAP is 68 mmHg. What is the priority nursing action? | Notify the physician immediately and obtain a 12-lead ECG. New AF is a known complication of dobutamine (β1 chronotropy). Rate control or cardioversion may be required. Do not independently change the dobutamine dose without a physician order. See the cardiac arrhythmias nursing guide for AF management principles. |
Clinical sources
- De Backer D, et al. “Comparison of dopamine and norepinephrine in the treatment of shock.” New England Journal of Medicine, 2010. (SOAP II trial)
- Rhodes A, et al. “Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.” Intensive Care Medicine, 2017.
- Evans L, et al. “Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.” Critical Care Medicine, 2021.
- Russell JA, et al. “Vasopressin versus norepinephrine infusion in patients with septic shock.” New England Journal of Medicine, 2008. (VASST trial)
- Overgaard CB, Dzavík V. “Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease.” Circulation, 2008.
- StatPearls. “Vasopressors.” NCBI Bookshelf. Updated 2024.
- StatPearls. “Inotropes.” NCBI Bookshelf. Updated 2024.
- Hollenberg SM. “Vasoactive drugs in circulatory shock.” American Journal of Respiratory and Critical Care Medicine, 2011.
- Wohl DA, et al. “Milrinone: an overview.” Critical Care Nursing Quarterly, 2019.
- American Heart Association. ACLS Provider Manual, 2020.